More Business Wire
View Older Stories View Newer Stories-
Palliser Capital Publishes Value Enhancement Plan for Toyo Tires
-
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2025 ASCO Annual Meeting
-
Faraday Future Holds First Annual Stockholders’ Day, Company Provides FX Product Updates, Confirms FX Super One Launch Timing, and Secures 600 New Deposits from Multi-Channel Network (MCN) Agencies
-
Hyundai Card Becomes First in Asia to Achieve UL Solutions Healthy Building Verifications for Cultural and Leisure Facilities
-
PKKP and Rio Tinto sign Co-Management Agreement
-
Union Remains at the Table - WSIB Stalls as Strike Continues
-
Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
-
DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
-
Announcing Balaji Karumanchi as Founder & CEO of Excelhire – The AI-Agentic Hiring Intelligence Platform
-
Introducing Tempus One in the EHR with Integrated Guidelines
-
IMFINZI® (durvalumab) regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial
-
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
-
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
-
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
-
Research Presented by The US Oncology Network at ASCO 2025 Demonstrates Significant Cost Savings in Community Oncology Setting with Pharmacist-Driven Interventions
-
Hibiki Path Advisors Launch a Public Campaign as the Largest Shareholder of JAPAN PURE CHEMICAL CO., LTD.
-
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
-
University of Phoenix Announces 2025 UOPX Faculty of the Year Award Recipients
-
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
-
ispace Completes Success 8 of Mission 2 Milestones
-
New Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
-
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti
-
ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY-Gastric04 Pha
-
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Neg
-
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025
-
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
-
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
-
Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American So
-
High School Students Named Best in America at the Council for Economic Education’s 2025 National Economics Challenge
-
ConcertAI Provides Intelligent Automation of ASCO® Guidelines into its Generative and Agentic AI Precision Suite™ and CancerLinQ® SmartLinQ™ Solutions
-
Delaware Court Further Extends Topping Period for Citgo Sale Process to June 18, 2025; Confirms Other Deadlines
-
Syncora Guarantee Inc. Announces the Availability of Certain Financial Information
-
EverGen Infrastructure Reports Q1 2025 Results
-
Everybody Loves Languages Reports Financial Results for the First Quarter Ended March 31, 2025
-
KBRA Affirms and Withdraws Rating for Fortegra Financial Corp, Assigns Ratings for The Fortegra Group, Inc., and Fortegra Specialty Insurance Company, and Affirms Ratings for Debt and Fortegra's Key I
-
XTM Files Q1 2025 Interim Financial Results
-
KBRA Comments on Amendment to Sunnova’s Loan Guarantee Agreement with DOE
-
KBRA Assigns Ratings to the Senior Loans, Mezzanine Loans, and Junior Loans Issued by Keys Investor II, LLC
-
Leading Independent Proxy Advisor ISS Recommends Sherritt Shareholders Vote FOR All Resolutions and Director Nominees
-
DoorDash Announces Closing of Upsized $2.75 Billion Offering of 0% Convertible Senior Notes
-
Celanese Corporation to Participate in Fireside Discussion at Deutsche Bank 16th Annual Global Industrials and Materials Conference
-
Pearls of Southern California Middle Market Business Shine at 2025 ACG Awards
-
AM Best Affirms Credit Ratings of Nacional de Seguros S.A. Compañía de Seguros Generales
-
QVest Announces Name Change
-
Priority Financial Group Celebrates 20 Years of Innovation
-
SABA Announces Notification of Sources of Distributions
-
CoStar Group and Happening Technology End Dispute Amicably
-
BRW Announces Notification of Sources of Distributions
-
EDS Service Solutions Named a 2025 Georgia Fast 40 Honoree by ACG Atlanta for Third Year in a Row
